In the SSGXVIII/AIO trial, 7 (4.7%) of the 149 patients with KIT exon 11 mutations had GIST recurrence while the patient was on imatinib, whereas 6 (23.1%) of the 26 patients with KIT exon 9 mutations had recurrence during imatinib treatment [45]. Here, KIT is linked to gastrointestinal stromal tumor.